Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
Blood Journals Portfolio recently shared a post on X:
”The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”
Read the full article here.
The recently published article ”Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China” by De Zhou et al. in Blood sheds light on the possible positive results from combination of Ruxolitinib with Dexamethasone in HLH patients.
A phase 2 trial of the Ru-D regimen—ruxolitinib combined with dexamethasone—showed promising results in adults newly diagnosed with HLH of unknown triggers.
Among 28 patients, the overall response rate was 85.7%, with a 2-month overall survival rate of 85.7% and favorable 2-year survival in non-lymphoma-associated HLH cases.
The Ru-D regimen was well tolerated, supporting further investigation in a phase 3 trial.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Aug 8, 2026, 09:56Same Drug, Different Results – ESC Working Group on Cardiovascular Pharmacotherapy
-
Aug 8, 2026, 09:37Maxime Dely: Behind Every Machine, There Is a Human Story
-
Aug 8, 2026, 09:30Veronica Sanchez: What You Need to Know About CKM Syndrome
-
Aug 8, 2026, 09:15Danny Hsu: ISTH 2026 Podcast Highlights
-
Aug 8, 2026, 09:09Chonlatis Srichumpuang: Throwback to ISTH 2026 in Paris
-
Aug 8, 2026, 08:37Kim Phelan: Voices of the Symposium 2026
-
Aug 8, 2026, 08:29Abdulrahman Nasiri: Understanding and Managing Chronic Pain in Transfusion-Dependent Thalassemia
-
Aug 8, 2026, 07:59Korawit Juprasertporn: Call for Papers – Thrombosis and Antithrombotic Therapy
-
Aug 8, 2026, 07:13Myth vs Fact – ‘An ITP diagnosis means life stops’ – ITP Support Association